138 related articles for article (PubMed ID: 25692853)
1. Efficacy of Rapamycin in Tuberous Sclerosis-Associated Hypopigmented Macules: Back to the Future.
Arbiser JL
JAMA Dermatol; 2015 Jul; 151(7):703-4. PubMed ID: 25692853
[No Abstract] [Full Text] [Related]
2. Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex.
Wataya-Kaneda M; Tanaka M; Yang L; Yang F; Tsuruta D; Nakamura A; Matsumoto S; Hamasaki T; Tanemura A; Katayama I
JAMA Dermatol; 2015 Jul; 151(7):722-30. PubMed ID: 25692384
[TBL] [Abstract][Full Text] [Related]
3. Dysregulation of autophagy in melanocytes contributes to hypopigmented macules in tuberous sclerosis complex.
Yang F; Yang L; Wataya-Kaneda M; Hasegawa J; Yoshimori T; Tanemura A; Tsuruta D; Katayama I
J Dermatol Sci; 2018 Feb; 89(2):155-164. PubMed ID: 29146131
[TBL] [Abstract][Full Text] [Related]
4. Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis.
Knöpfel N; Martín-Santiago A; Bauza A; Hervás JA
Actas Dermosifiliogr; 2014 Oct; 105(8):802-3. PubMed ID: 24355193
[No Abstract] [Full Text] [Related]
5. Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors.
Lam C; Bouffet E; Tabori U; Mabbott D; Taylor M; Bartels U
Pediatr Blood Cancer; 2010 Mar; 54(3):476-9. PubMed ID: 19856393
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of subungual fibromas of tuberous sclerosis with topical rapamycin.
Muzic JG; Kindle SA; Tollefson MM
JAMA Dermatol; 2014 Sep; 150(9):1024-5. PubMed ID: 24919623
[No Abstract] [Full Text] [Related]
7. Topical use of mammalian target of rapamycin inhibitors in dermatology: A systematic review with meta-analysis.
Leducq S; Giraudeau B; Tavernier E; Maruani A
J Am Acad Dermatol; 2019 Mar; 80(3):735-742. PubMed ID: 30744877
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus for Retinal Astrocytic Hamartoma Associated with Tuberous Sclerosis Complex.
Zhang ZQ; Shen C; Long Q; Yang ZK; Dai RP; Wang J; Zhang W; Pan Q; Zhu Z; Xu KF
Ophthalmology; 2015 Sep; 122(9):1947-9. PubMed ID: 25912145
[No Abstract] [Full Text] [Related]
9. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex.
Wienecke R; Fackler I; Linsenmaier U; Mayer K; Licht T; Kretzler M
Am J Kidney Dis; 2006 Sep; 48(3):e27-9. PubMed ID: 16931204
[TBL] [Abstract][Full Text] [Related]
10. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
11. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.
Hofbauer GF; Marcollo-Pini A; Corsenca A; Kistler AD; French LE; Wüthrich RP; Serra AL
Br J Dermatol; 2008 Aug; 159(2):473-5. PubMed ID: 18547304
[TBL] [Abstract][Full Text] [Related]
12. A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex.
Wataya-Kaneda M; Tanaka M; Nakamura A; Matsumoto S; Katayama I
Arch Dermatol; 2012 Jan; 148(1):138-9. PubMed ID: 22250258
[No Abstract] [Full Text] [Related]
13. Effects of rapamycin on angiomyolipomas in patients with tuberous sclerosis.
Cabrera López C; Martí T; Catalá V; Torres F; Mateu S; Ballarín Castán J; Torra Balcells R
Nefrologia; 2011; 31(3):292-8. PubMed ID: 21629335
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin has a beneficial effect on controlling epilepsy in children with tuberous sclerosis complex: results of 7 children from a cohort of 86.
Canpolat M; Per H; Gumus H; Yikilmaz A; Unal E; Patiroglu T; Cinar L; Kurtsoy A; Kumandas S
Childs Nerv Syst; 2014 Feb; 30(2):227-40. PubMed ID: 23743820
[TBL] [Abstract][Full Text] [Related]
15. Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus.
Nathan N; Wang JA; Li S; Cowen EW; Haughey M; Moss J; Darling TN
J Am Acad Dermatol; 2015 Nov; 73(5):802-8. PubMed ID: 26365597
[TBL] [Abstract][Full Text] [Related]
16. Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment.
Jozwiak J; Jozwiak S; Oldak M
Med Res Rev; 2006 Mar; 26(2):160-80. PubMed ID: 16329102
[TBL] [Abstract][Full Text] [Related]
17. Fibrous Cephalic Plaque in Tuberous Sclerosis Complex: Treatment With 0.2% Rapamycin.
Giacaman A; Martín-Santiago A
Actas Dermosifiliogr (Engl Ed); 2019 Jun; 110(5):e13. PubMed ID: 30846165
[No Abstract] [Full Text] [Related]
18. Sirolimus and tuberous sclerosis-associated renal angiomyolipomas.
Krischock L; Beach R; Taylor J
Arch Dis Child; 2010 May; 95(5):391-2. PubMed ID: 20457704
[TBL] [Abstract][Full Text] [Related]
19. Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin.
Cheng S; Hawkins C; Taylor MD; Bartels U
Pediatr Neurol; 2015 Sep; 53(3):238-242.e1. PubMed ID: 26173783
[TBL] [Abstract][Full Text] [Related]
20. Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response.
Truchuelo T; Díaz-Ley B; Ríos L; Alcántara J; Jaén P
Dermatol Online J; 2012 Jan; 18(1):15. PubMed ID: 22301052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
